Vancomycin hydrochloride is a glycopeptide antibiotic active against a wide variety of Gram-positive bacteria.
Indication: Used in the treatment of patients with Clostridium difficile infection (CDI).
Application: Administered orally.
Dosage form |
Hard gelatine capsules |
|||||
Strength |
125 mg 250 mg |
|||||
Compliance |
Currently there is no monograph for vancomycin hydrochloride capsules in Ph.Eur. USP |
|||||
Manufacturing site |
CMO for Xellia Pharmaceuticals ApS |
|||||
Release site |
Xellia Pharmaceuticals ApS, Copenhagen, Denmark |
|||||
Site registered |
EU GMP issued by Medicines and Healthcare products Regulatory Agency US FDA Other Health Authorities |
|||||
Batch size |
|
|||||
Regulatory documentation |
EU dossier |
|||||
Packaging material |
|
|||||
Shelf life |
| |||||
Storage conditions |
| |||||
